RxDoctor Payments Data

Mitchell Kerner

Adult Health · Williamsville, NYNPI 1356975940

Payments from drug & device makers

$13,026in general payments, 2019–2025

Across 609 payments — averaging $21.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • GSK$1K
  • Boehringer Ingelheim$1K
  • Sanofi$935
  • Actelion Pharmaceuticals US, Inc.$889
  • Grifols USA, LLC$617
  • plus $6K from 39 others

What the payments were for

  • Travel & lodging$180%
  • Food & beverage$12,90999%
  • Education$991%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,026 in reported general payments places this provider in the 95th percentile of 3,828 adult health providers in New York.

See all adult health providers in New York

Medicare billing

Part B allowed, 2024
$12,295
Medicare patients
112
Services billed
187

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter267$202,791
Breztri AerosphereBudesonide/Glycopyr/Formoterol210$147,331
NucalaMepolizumab33$128,895
Breo ElliptaFluticasone/Vilanterol104$49,699
Stiolto RespimatTiotropium Br/Olodaterol Hcl65$46,192
Dupixent SyringeDupilumab11$40,538
Spiriva RespimatTiotropium Bromide41$27,250
Fluticasone-SalmeterolFluticasone Propion/Salmeterol128$27,186
SymbicortBudesonide/Formoterol Fumarate45$16,576
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr23$13,440
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate48$12,662
Wixela InhubFluticasone Propion/Salmeterol23$8,556
Albuterol Sulfate HfaAlbuterol Sulfate266$8,524
Arnuity ElliptaFluticasone Furoate19$3,900
Tiotropium Bromide12$3,702

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$1,470$398,726446 claims
AstraZenecaBreztri Aerosphere, Symbicort, Pulmicort Flexhaler$2,303$167,028266 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$1,194$73,442106 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,828 adult health providers in New York.

Other adult health in Williamsville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →